Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

Wealthy500 Jun. 25 at 4:58 AM

$SLS $WEN $PFE $LLY $MRK

0 · Reply

StocktwitsNews Jun. 25 at 4:14 AM

VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play $VKTX $NVO $PFE $LLY https://stocktwits.com/news/equity/markets/vktx-bulls-q3-obesity-data-novo-big-pharma-buyout/cZ1G5RqR7QQ

1 · Reply

sam92 Jun. 25 at 3:29 AM

$PFE Should start heading higher now Pfizer Dismissed from Antitrust Lawsuit, Reducing Legal Exposure Written by Emily J. Thompson, Senior Investment Analyst https://intellectia.ai/news/monitor/pfizer-dismissed-from-antitrust-lawsuit-reducing-legal-exposure

0 · Reply

umiak1 Jun. 25 at 2:35 AM

$PFE “ PFE has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported Wednesday, citing a court decision. Chief Judge of the federal district court in Connecticut, said in a Tuesday ruling the states failed to establish that Pfizer and its former Greenstone unit colluded with competitors to rig bids and allocate customers for drug products, according to the report. Pfizer is pleased with the Court's decision to grant summary judgment and dismiss all claims against Pfizer- which had no involvement in the alleged conduct and should never have been named in the complaint to begin with", a Pfizer spokesperson said in an emailed statement to MT Newswires.”

0 · Reply

Zero12345 Jun. 25 at 12:45 AM

$PFE People on this board are too pessimistic right now... AI Bob & Mike posted today on Yahoo Finance: "One thing the Al trading computers know is they are running out of time to get into PFE. PFE has beaten earnings for the last 4Q in a row and that Q 1 showed real growth as new products are doing better than was forecasted and that the $7 billion in cost cuts put the floor in the earnings with only upside. Only a matter of time before the Al trading computers start attacking the over priced tech stocks because that is were the real money to be made is." "There are four core golden eggs (FDA-approved therapies) that Seagen fully commercialized and brought to Pfizer at the time of the acquisition. Pfizer was not buying the golden eggs. We are acquiring the goose that is laying the golden eggs. So one egg is a little scrambled, but it's still gonna produce."

0 · Reply

BillionerOfKing Jun. 25 at 12:41 AM

$PFE Current Stock Price: $24.05 Contracts to trade: $24.0 PFE Jun 26 2026 Call Entry: $0.24 Exit: $0.41 ROI: 70% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Micheal_Pothead Jun. 25 at 12:10 AM

$PFE you would have had to buy this stock 22 years ago to have out paced inflation and been positive on your investment

1 · Reply

Cedenmo Jun. 25 at 12:07 AM

$PFE As a shareholder of this and $TGTX, i say write the check for $20B (I’d prefer more PFE shares though as I love the price and yield here). TGTX has a sure winner in Briumvi which can easily do $5-10B in big hands. Expanding franchise to SubQ and a platform to other indications. Then Azer cel as well. Would love to stay vested in Briumvi’s success here post-TGTX.

1 · Reply

MR2601 Jun. 25 at 12:03 AM

$PFE top management is full of bureaucratic attitude not business man like approach ; their Seagen acquisition was a mess as they paid so high for it. Rather they could pick up some small outfits like NUBV , CADL,URGN and get better leverage . These top guys are full of themselves and as a result the SP is suffering just from a Phase 3 bad data and uncertainty .

0 · Reply

Micheal_Pothead Jun. 24 at 11:58 PM

$PFE what if we paid the LLY CEO like 200m a year to swap over

0 · Reply

Pfizer Declares Third-Quarter 2026 Dividend

2026-06-24T18:20:21.000Z - 11 hours ago

Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

Jun 24, 2026, 2:10 PM EDT - 12 hours ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

2026-06-24T15:25:12.000Z - 14 hours ago

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

Jun 24, 2026, 10:51 AM EDT - 15 hours ago

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 23, 2026, 12:10 PM EDT - 1 day ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 10:00 AM EDT - 1 day ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 22, 2026, 4:43 PM EDT - 2 days ago

Pfizer's experimental drug misses main goal of lung cancer trial

2026-06-22T20:33:17.000Z - 2 days ago

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

Jun 22, 2026, 4:30 PM EDT - 2 days ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 2:32 PM EDT - 2 days ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

2026-06-18T18:35:11.000Z - 6 days ago

Pfizer (PFE) Shares Sink After Surprise CFO Exit

2026-06-18T17:30:31.000Z - 6 days ago

Pfizer reaffirms all components of FY26 guidance

2026-06-18T10:52:33.000Z - 6 days ago

Pfizer CFO Dave Denton to step down, Cecile Guegan named interim CFO

Jun 18, 2026, 6:52 AM EDT - 6 days ago

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:45 AM EDT - 6 days ago

Pfizer Announces Chief Financial Officer Transition

Jun 10, 2026, 7:56 AM EDT - 14 days ago

Pfizer CEO warns German investment at risk over drug pricing policies

2026-06-09T21:05:52.000Z - 15 days ago

Pfizer upgraded to Sector Perform from Underperform at RBC Capital

2026-06-09T21:05:12.000Z - 15 days ago

Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward

Jun 9, 2026, 2:07 PM EDT - 15 days ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Jun 9, 2026, 9:20 AM EDT - 15 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

Jun 9, 2026, 3:20 AM EDT - 15 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T10:51:57.000Z - 16 days ago

Pfizer says FDA approves expanded indication for Hympavzi

Jun 8, 2026, 6:49 AM EDT - 16 days ago

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:45 AM EDT - 16 days ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

2026-06-07T22:00:49.000Z - 17 days ago

Pfizer presents results from Phase 2b studies of berobenatide

Jun 6, 2026, 11:00 AM EDT - 18 days ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 18 days ago

Pfizer Slides: Study update

Jun 6, 2026, 9:06 AM EDT - 18 days ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:00 AM EDT - 18 days ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 4, 2026, 10:00 AM EDT - 20 days ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 6:40 AM EDT - 20 days ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Jun 3, 2026, 2:00 PM EDT - 21 days ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 10:00 AM EDT - 23 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 31, 2026, 8:00 AM EDT - 24 days ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 30, 2026, 9:22 AM EDT - 25 days ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA

May 30, 2026, 8:00 AM EDT - 25 days ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 29, 2026, 8:00 AM EDT - 26 days ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 28, 2026, 11:10 PM EDT - 27 days ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 7:19 PM EDT - 27 days ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:00 PM EDT - 27 days ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 27 days ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 27, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 20, 2026, 9:00 AM EDT - 5 weeks ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 5:08 AM EDT - 5 weeks ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:05 AM EDT - 5 weeks ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 18, 2026, 8:00 AM EDT - 5 weeks ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 14, 2026, 2:22 PM EDT - 5 weeks ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

May 13, 2026, 6:45 AM EDT - 6 weeks ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

May 5, 2026, 4:09 PM EDT - 7 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:02 PM EDT - 7 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 11:30 AM EDT - 7 weeks ago

3 Dividend Stocks for May 2026

SYY WSO

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Slides: Q1 2026

May 5, 2026, 8:35 AM EDT - 7 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 7:23 AM EDT - 7 weeks ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:06 AM EDT - 7 weeks ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:05 AM EDT - 7 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

May 5, 2026, 6:55 AM EDT - 7 weeks ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:51 AM EDT - 7 weeks ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 1, 2026, 12:37 PM EDT - 7 weeks ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Apr 29, 2026, 7:42 AM EDT - 2 months ago

Pfizer's blood cancer drug meets main goal in late-stage trial

Wealthy500 Jun. 25 at 4:58 AM

$SLS $WEN $PFE $LLY $MRK

0 · Reply

StocktwitsNews Jun. 25 at 4:14 AM

1 · Reply

sam92 Jun. 25 at 3:29 AM

0 · Reply

umiak1 Jun. 25 at 2:35 AM

0 · Reply

Zero12345 Jun. 25 at 12:45 AM

0 · Reply

BillionerOfKing Jun. 25 at 12:41 AM

0 · Reply

Micheal_Pothead Jun. 25 at 12:10 AM

$PFE you would have had to buy this stock 22 years ago to have out paced inflation and been positive on your investment

1 · Reply

Cedenmo Jun. 25 at 12:07 AM

1 · Reply

MR2601 Jun. 25 at 12:03 AM

0 · Reply

Micheal_Pothead Jun. 24 at 11:58 PM

$PFE what if we paid the LLY CEO like 200m a year to swap over

0 · Reply

dewmoore Jun. 24 at 11:38 PM

$SLS Follow the data/the numbers don't lie! Every morning we have the DAILY pre-market shakeout! Mon: Pre-market low $8.19 ➜ bought up to close at $8.53 Tue: Pre-market dipped to $8.27 ➜ stair-stepped to close at $9.07 Wed: Pre-market dipped to $8.95 ➜ pushed over $9.15 near 52-week highs IBKR Availability: ZERO shares. Borrow Fee: Sitting at its absolute monthly peak of 149% (with Robinhood touching 261%+). The Close: Massive buy-side imbalances right into the bell (153k paired vs. 112k imbalance). They paint the tape red in thin early hours to get fools to sell, but when the bell rings the dip is quickly bought up LOL ! Shorts are trapped paying triple-digit premiums on a position they can’t even hedge or add to. It's a textbook pressure cooker. Hold the line, turn off share lending, and remove the stop losses. It’s a supply-demand mismatch ready to snap. 🚀 $WEN $PFE $LLY $MRK

1 · Reply

PFElinepfrenzy1990 Jun. 24 at 10:20 PM

$PFE 💪🏻

1 · Reply

Typecheck Jun. 24 at 10:02 PM

$PFE The biggest problem with Al Bourla and his band of fools is that they believe spending 43 Billion dollars for a company so that they can make 5 billion dollars within 10 years is a good deal. All recent acquisitions are failure or colossal failure.

2 · Reply

PFElinepfrenzy1990 Jun. 24 at 9:37 PM

$PFE *Insert smol violin 🎻*

0 · Reply

A_Train1 Jun. 24 at 9:14 PM

$PFE well, I guess we’ll have another dump in July? I never look forward to dividend day anymore. Isn’t that a shame?

2 · Reply

StocktwitsNews Jun. 24 at 9:14 PM

PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win $PFE $VTI $VOO https://stocktwits.com/news/equity/markets/pfe-stock-continues-to-drop-as-lung-cancer-trial-disappointment-overshadows-ibrance-win/cZKyn58R7Qc

0 · Reply

Micheal_Pothead Jun. 24 at 8:56 PM

$PFE yay… Chip stocks are pumping again..

3 · Reply

A_Train1 Jun. 24 at 8:38 PM

$PFE this latest failure on the phase 3 has got to drive some change, no? I just cannot see them continuing down this path. It is clear that Wall Street does not like the current leadership, and every success is met with resistance while every failure is amplified

1 · Reply

sam92 Jun. 24 at 8:11 PM

$PFE Pfizer declares $0.43 dividend

0 · Reply

reyofhope Jun. 24 at 8:01 PM

$PFE I put 50 thousand in this nonsense last year I should have put it in amd and I would have been on a beach. We all screwed up here guys. Don't trust this Greek old fool. I'm so pissed right now and now I'm stuck here waiting for this idiot to turn this around.

3 · Reply

PFElinepfrenzy1990 Jun. 24 at 7:57 PM

$PFE - Sad yay https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Declares-Third-Quarter-2026-Dividend/default.aspx

1 · Reply

sam92 Jun. 24 at 7:55 PM

$PFE Pfizer granted FDA label expansion for breast cancer drug, Ibrance

1 · Reply

Market Cap	140.89B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.20
Forward PE	8.40
Profit Margin	12.42%
Debt to Equity Ratio	0.71

Volume	76,962,600
Avg Vol	38,514,320
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	4%
Beta	0.34
Analysts	Sell
Price Target	$29.28